Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants.
Calreticulin
/ genetics
Cell Transformation, Neoplastic
/ genetics
DNA Repair
/ genetics
Down-Regulation
Endoplasmic Reticulum Stress
/ genetics
Gene Knockdown Techniques
Humans
INDEL Mutation
K562 Cells
Mitochondrial Proteins
/ antagonists & inhibitors
Mutant Proteins
/ genetics
Oxidative Stress
/ genetics
Phenanthrenes
/ pharmacology
Primary Myelofibrosis
/ genetics
Recombinant Proteins
/ genetics
Superoxide Dismutase
/ metabolism
Thrombocythemia, Essential
/ genetics
Transcriptome
Unfolded Protein Response
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 07 2019
22 07 2019
Historique:
received:
31
07
2018
accepted:
03
07
2019
entrez:
24
7
2019
pubmed:
25
7
2019
medline:
24
10
2020
Statut:
epublish
Résumé
Somatic mutations of calreticulin (CALR) have been described in approximately 60-80% of JAK2 and MPL unmutated Essential Thrombocythemia and Primary Myelofibrosis patients. CALR is an endoplasmic reticulum (ER) chaperone responsible for proper protein folding and calcium retention. Recent data demonstrated that the TPO receptor (MPL) is essential for the development of CALR mutant-driven Myeloproliferative Neoplasms (MPNs). However, the precise mechanism of action of CALR mutants haven't been fully unraveled. In this study, we showed that CALR mutants impair the ability to respond to the ER stress and reduce the activation of the pro-apoptotic pathway of the unfolded protein response (UPR). Moreover, our data demonstrated that CALR mutations induce increased sensitivity to oxidative stress, leading to increase oxidative DNA damage. We finally demonstrated that the downmodulation of OXR1 in CALR-mutated cells could be one of the molecular mechanisms responsible for the increased sensitivity to oxidative stress mediated by mutant CALR. Altogether, our data identify novel mechanisms collaborating with MPL activation in CALR-mediated cellular transformation. CALR mutants negatively impact on the capability of cells to respond to oxidative stress leading to genomic instability and on the ability to react to ER stress, causing resistance to UPR-induced apoptosis.
Identifiants
pubmed: 31332222
doi: 10.1038/s41598-019-46843-z
pii: 10.1038/s41598-019-46843-z
pmc: PMC6646313
doi:
Substances chimiques
CALR protein, human
0
Calreticulin
0
Mitochondrial Proteins
0
Mutant Proteins
0
OXR1 protein, human
0
Phenanthrenes
0
Recombinant Proteins
0
miltirone
27210-57-7
Superoxide Dismutase
EC 1.15.1.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10558Références
Stem Cells. 1996;14 Suppl 1:232-9
pubmed: 11012226
Blood. 2016 Mar 10;127(10):1307-16
pubmed: 26817954
Blood. 2016 Mar 10;127(10):1317-24
pubmed: 26608331
J Invest Dermatol. 2014 Jan;134(1):183-191
pubmed: 23771121
Blood. 2014 Sep 25;124(13):e21-32
pubmed: 25097177
Leukemia. 2013 Nov;27(11):2187-95
pubmed: 23558526
Oncotarget. 2017 Jul 25;8(30):49451-49469
pubmed: 28533480
J Cell Sci. 2000 Nov;113 Pt 21:3697-702
pubmed: 11034898
Leukemia. 2018 Feb;32(2):438-449
pubmed: 28745329
Nature. 1991 Jan 31;349(6308):431-4
pubmed: 1992344
Br J Haematol. 2016 Jun;173(6):938-40
pubmed: 26303809
Stem Cells. 2008 Apr;26(4):950-9
pubmed: 18192237
Mol Cell Biol. 1992 Apr;12(4):1872-8
pubmed: 1372390
Int J Biochem Cell Biol. 2012 Jun;44(6):842-6
pubmed: 22373697
Free Radic Biol Med. 2014 Dec;77:41-8
pubmed: 25236744
Exp Hematol. 2010 Nov;38(11):1058-65
pubmed: 20655352
Cancer Res. 2004 Sep 1;64(17):5943-7
pubmed: 15342372
Haematologica. 2010 Dec;95(12):2153-6
pubmed: 20823136
Oncotarget. 2015 Aug 28;6(25):20977-92
pubmed: 26023795
Pharmacol Res. 2017 Jun;120:258-266
pubmed: 28396092
Nature. 1994 Feb 3;367(6462):480-3
pubmed: 8107809
Toxicon. 2016 Feb;110:56-67
pubmed: 26704293
Mol Cell Biol. 2002 Nov;22(21):7405-16
pubmed: 12370288
Methods Mol Biol. 2012;920:613-26
pubmed: 22941631
Nature. 1994 Feb 3;367(6462):476-80
pubmed: 8107808
J Clin Invest. 2005 Oct;115(10):2656-64
pubmed: 16200199
JCI Insight. 2018 Nov 15;3(22):
pubmed: 30429377
Nat Cell Biol. 2000 Jun;2(6):326-32
pubmed: 10854322
Biol Chem. 2006 Apr;387(4):373-9
pubmed: 16606334
Cancer Discov. 2016 Apr;6(4):368-81
pubmed: 26951227
Am J Physiol Cell Physiol. 2006 Jan;290(1):C208-21
pubmed: 16135540
Sci Rep. 2016 Feb 05;6:20585
pubmed: 26848099
N Engl J Med. 2013 Dec 19;369(25):2391-2405
pubmed: 24325359
Cell Death Differ. 2015 Dec;22(12):1906-21
pubmed: 25857263
Blood. 2016 Mar 10;127(10):1325-35
pubmed: 26668133
Nat Rev Cancer. 2008 Nov;8(11):851-64
pubmed: 18846101
Trends Cell Biol. 2004 Jan;14(1):20-8
pubmed: 14729177
Free Radic Biol Med. 2001 Jun 15;30(12):1418-25
pubmed: 11390187
Sci Rep. 2015 Nov 30;5:17409
pubmed: 26616534
N Engl J Med. 2013 Dec 19;369(25):2379-90
pubmed: 24325356
Biochem J. 1999 Dec 1;344 Pt 2:281-92
pubmed: 10567207
Mol Biol Cell. 2006 Jul;17(7):3095-107
pubmed: 16672378
J Cell Biol. 2000 Aug 21;150(4):731-40
pubmed: 10952999